Meet the Executive Team

Brian Carrico, President & Chief Executive Officer

Brian Carrico

President & Chief Executive Officer

Brian Carrico is the President and Chief Executive Officer of NeurAxis, Inc., a growth stage med-tech company addressing chronic and debilitating conditions in children. Brian also serves as a Director on the Board for NeurAxis. He joined NeurAxis in 2012, and during his tenure at NeurAxis, Brian has held multiple leadership positions of increasing responsibility, including Vice President of Sales and President before becoming CEO on January 1, 2018. As an early employee in the Company’s life cycle, Brian was instrumental in setting the strategic agenda for NeurAxis, raising start-up capital, championing new product development, and bringing a first of its kind technology to market. He has worked with countless thought leaders throughout the country to bring evidence based peripheral neuromodulation technology and a new standard of care from idea to placebo-controlled trials through the FDA and to the commercialization stage.

Prior to joining NeurAxis, Brian worked selling in the operating room at Bard Medical and in the Cath lab at St. Jude Medical.  He attended Indiana State University and holds a Bachelor of Science in Business Marketing.  Brian’s goal is to lead execution of the company’s strategy while staying focused on the long-term mission to create value for all the NeurAxis team, patients, providers, and shareholders.

Brian Carrico, President & Chief Executive Officer

Timothy Henrichs

Chief Financial Officer

Mr. Henrichs brings over 20 years of global leadership experience across several industries, including healthcare, home improvement, retail, software, and education. Most recently, Mr. Henrichs served as a member of the NeurAxis Board since August 8, 2023, and the Chief Financial Officer of Renovo Home Partners since 2022. He also served as the Executive Vice President and Chief Financial Officer of Follett Corporation from 2008 to 2022 and Global Controller of General Electric Company’s Healthcare Clinical Systems division responsible for the manufacture and distribution of medical devices to the ultrasound, patient monitoring, and anesthesiology markets from 2005 to 2008 in addition to leadership positions at Federal Signal Corporation and Ernst & Young LLP. Mr. Henrichs earned his bachelor’s degree in accounting from the University of Notre Dame and is a Certified Public Accountant with an inactive license in the State of Illinois.

Brian Carrico, President & Chief Executive Officer

Dr. Adrian Miranda

Senior VP of Science & Technology and Chief Medical Officer

Dr. Miranda brings a unique background of research and clinical expertise to his role as Chief Medical Officer of NeurAxis. He is a Professor of Pediatrics and a board certified Pediatric Gastroenterologist. He obtained his undergraduate degree in Biology from San Diego State University and obtained his medical degree from the Medical College of Wisconsin. He completed his residency and subspecialty training in Pediatric Gastroenterology at Children’s Hospital of Wisconsin (CHW).

As a physician scientist, he has spent the past 15 years of his career investigating the pathophysiology of visceral and somatic pain, as well as exploring new therapeutic options. His focus has been on studying the effects of adverse early life events, neuroplasticity and the development of chronic pain. He has an extensive publication record and has lectured nationally and internationally. His studies have translated to increased awareness of the importance of pain management and have significantly contributed to an increased understanding of the pathophysiology of pain.

He has received numerous accolades for his work including the prestigious “Basic Science Award” from the IFFGD foundation, the clinical and basic science awards from the national pediatric gastroenterology society (NASPGHAN), and the REGAL Award for outstanding research in the field of Gastroenterology, amongst others. Dr. Miranda has received funding from the National Institute of Health (NIH) to advance pain research and has served as a NIH study section reviewer. He has also been appointed to numerous national and international committees. Most recently he served on the Rome – European Medicines Agency (EMA) Pediatric Committee in charge of developing guidelines for endpoints and outcomes of clinical trials in children with irritable bowel syndrome.

Dr. Miranda has been recognized by his peers as an outstanding teacher and clinician. He is a recipient of the “Outstanding Teacher of the Full-Time Pediatric Faculty” award at CHW and has been included in the “Best Doctors in America” list consistently for the past 8 years.

Brian Carrico, President & Chief Executive Officer

Dr. Chris Brown DDS, MPS

Director of Innovation

Dr. Brown’s degrees include a BS from the University of Indianapolis, a Doctorate (DDS) from the Indiana University School of Dentistry, and a Master’s of Professional Studies ( MPS) from Lynn University in Biomechanical Trauma. He served on the board of directors of The American Academy of Pain Management for 15 years and a term as the President. He served for 6 years in the United States Army Reserve achieving the rank of Captain and acting clinic chief.

Dr. Brown has authored many articles and text book chapters regarding the diagnosis and treatment of acute and chronic pain, biomechanical trauma, and the physics involved in energy transfer through human tissue.

In addition to the American Dental Association he retains membership in the Society of Automobile Engineers, and the North American Neuromuscular Society ( NANS). He has played an active part in the theory and design of NeurAxis devices holding multiple device and method patents.

In addition to his role as Director of Innovation at NeurAxis Dr. Brown continues in private practice in Indiana with a concentration in Head, neck, and facial pain advancing clinical applications of Percutaneous electrical nerve field stimulation ( PENFS).

Brian Carrico, President & Chief Executive Officer

Dr. Tom Carrico

Chief Regulatory Officer

Dr. Carrico is the Chief Regulatory Officer of NeurAxis, Inc. He has over 40 years of experience in the healthcare field, including 30 years prior to coming onboard at NeurAxis in 2012 and has been passionately involved in the study and application of techniques and treatments that directly affect the autonomic nervous system, especially regarding homeostasis and balance of the parasympathetic and the sympathetic nervous system.

Dr. Carrico has a unique history of working with attorneys on state and national boards, which has positioned him to integrate into regulatory responsibilities at NeurAxis. While working with Dr. Miranda and outside counsel, he led the process to get the company’s first 510(K) in 2014 followed by two successful DeNovo clearances. Additionally, he authored the company’s first OIG Compliance Program in 2015 and is responsible for its expansion and development, successfully acquired the past FSS/VA and DAPA contracts for the company’s products, is involved in product development and manufacturing, successfully navigated an FDA audit, and is an advisor to the NeurAxis Executive Team. Dr. Carrico was responsible for development and implementation of the NeurAxis Quality Management System in 2020, by partnering with FDA counsel and outside experts on the subject. Dr. Carrico is also an inventor on one of the NeurAxis Patents and has assigned the auricular portion of the invention over to NeurAxis.

Dr. Carrico received his undergraduate education from Indiana University and his Doctorate from Palmer College of Chiropractic. Dr. Carrico’s goal is to continue to provide his acquired knowledge and experience to advance NeurAxis as a company and the technology it is focused on developing, especially to help children and the millions of people whose lives will improve because of the NeurAxis portfolio.

Neuromodulation Therapies For Chronic And Debilitating Conditions In Children

Neuromodulation Therapies For Chronic And Debilitating Conditions In Children

Targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interactions (DGBIs).